Vincristine Sulfate
Brand Names: Vincristine Sulfate Generic
Methodology & AI Transparency ⓘ
Vincristine Sulfate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Vincristine Sulfate Injection is indicated in acute leukemia.
- 2 Real-world patient consensus: Real-world cohort score of 91% across 10 de-identified Vincristine Sulfate entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $62.37 mail/discount cash up to $152.81 uninsured retail (federal NADAC $1.3300).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Vincristine Sulfate include constipation (8.2%), nausea (8.4%), headache (8.1%).
Ask our AI Specialists anything about Vincristine Sulfate
Vincristine Sulfate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.
CLINICAL PHARMACOLOGY The mechanisms of action of vincristine sulfate remain under investigation. The mechanism of action of vincristine sulfate has been related to the inhibition of microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Central nervous system leukemia has been reported in patients undergoing otherwise successful therapy with vincristine sulfate. This suggests that vincristine does not penetrate well into the cerebrospinal fluid. Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern following rapid intravenous injection.
Pharmacokinetic profiling of Vincristine Sulfate demonstrates an elimination half-life of Elimination kinetics span 5 to 16 hours per Vincristine Sulfate clinical pharmacology with Complete (~100%) parenteral systemic delivery for Vincristine Sulfate (1 mg/mL Injection, Solution) systemic bioavailability; clearance proceeds via systemic clearance of vincristine sulfate integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after vincristine sulfate administration.
Titration schedules for Vincristine Sulfate (1 mg/mL Injection, Solution → Response-guided Vincristine Sulfate dose modification under follow-up) require excluding contraindications patients with the demyelinating form of charcot–marie–tooth syndrome should not be given vincristine sulfate injection.; careful attention should be given to those conditions listed under warnings and precautions .; real-world patient logs highlight nausea (8.4% of reports), constipation (8.2% of reports), headache (8.1% of reports) alongside a 91.00% Worth-It consensus.
Chronic enzyme induction shortens Vincristine Sulfate persistence in plasma and reduces steady-state exposure.
Verify medication reconciliation lists so Vincristine Sulfate is not inadvertently duplicated with another vinca alkaloid.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Patients with the demyelinating form of Charcot–Marie–Tooth syndrome should not be given Vincristine Sulfate Injection.
- Careful attention should be given to those conditions listed under WARNINGS and PRECAUTIONS .
Logged Side-Effect Incidence (10 Reports)
Vincristine Sulfate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vincristine Sulfate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vincristine and dexamethasone pulses in addition to maintenance therapy among: What a 384-Participant Study Found Conversely, the total prevalence of chemotherapy-induced thrombocytopenia was higher for patients in the treatment group than in the control group (88.9% vs. American journal of hematology • 2023-06-15 • Phase III Randomized Trial | N = 384 | 87/100 | PMID 36877527 ↗ |
| Can This Approach Help? Inside the Latest Research on Subclonal TP53 mutations are frequent and predict resistance to In summary, subclonal TP53 mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. Blood advances • 2023-09-12 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37379264 ↗ |
Vincristine Sulfate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3300/unit (~$39.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $152.81 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $62.37 / mo | View logs ↓ |
Vincristine Sulfate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vincristine Sulfate RxNorm Concept ID | 1863343 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $152.81 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $62.37 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vincristine Sulfate Patient Community, Cohort Filters & Dosage Logs
Deterministic Vincristine Sulfate reference combining NIH RxNorm (1863343), Medicaid NADAC ($1.3300/unit), and anonymous cohort outcomes (91% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vincristine Sulfate community threads and patient logs by age, biological sex, dosage, and treatment duration.